Corazon (corsee) D. Sanders - 29 Sep 2026 Form 4 Insider Report for Legend Biotech Corp (LEGN)

Reporting relationship: Director
Issuer ticker: LEGN
Reported as of: 29 Sep 2026
Net transaction value: -$258,920
SEC form: 4
Accepted by SEC: 01 Oct 2026, 16:04:09 UTC
Prior SEC filing: 28 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Staloff, Attorney-in-Fact

Filing notes and source

Key filing fact

Corazon (corsee) D. Sanders filed Form 4 for Legend Biotech Corp (LEGN) on 01 Oct 2026.

Key facts

This page summarizes Corazon (corsee) D. Sanders's Form 4 filing for Legend Biotech Corp (LEGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Oct 2026, 16:04.

Change

Previous filing in this sequence was filed on 28 Sep 2026.
Current net transaction value: -$258,920.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796536 Primary reporting owner

Sanders Corazon (Corsee) D.

Relationship: Director
Address: C/O LEGEND BIOTECH CORP, 77 CORPORATE DRIVE, 4TH FLOOR, BRIDGEWATER
Signature: /s/ Robert Staloff, Attorney-in-Fact
Signature date: 01 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEGN transaction

Ordinary Shares

Sale

Transaction value: $258,920
Shares: -27,370
Change %: -34%
Price: $9.46
Shares after: 52,731
Date: 29 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

Footnote F2

The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.